Abstract
Aurora inhibitors have been extensively studied as potential novel anticancer agents. At least four compounds are now under clinical evaluation. Banyu discloses aminopyridines and -pyrazines acting as selective Aurora-A inhibitors. The claimed compounds demonstrated low nanomolar activity in the biochemical assay and exhibit a 200-fold specificity on Aurora-A versus Aurora-B.
| Original language | English |
|---|---|
| Pages (from-to) | 255-261 |
| Number of pages | 7 |
| Journal | Expert Opinion on Therapeutic Patents |
| Volume | 17 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2007 |
Keywords
- Aurora-A
- Aurora-B
- Mitosis
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Pharmacology
- Law
Fingerprint Dive into the research topics of 'Aminopyridines: Selective Aurora-A inhibitors'. Together they form a unique fingerprint.
Cite this
Vianello, P. (2007). Aminopyridines: Selective Aurora-A inhibitors. Expert Opinion on Therapeutic Patents, 17(2), 255-261. https://doi.org/10.1517/13543776.17.2.255